List view / Grid view
Kesimpta was approved based on trial results showing the monthly injection significantly reduced the relapse rate and disability progression of MS patients compared to a currently approved treatment.
Researchers reveal that for early breast cancer a single dose of targeted intraoperative radiotherapy (TARGIT-IORT) is as effective at preventing breast cancer recurrence as the standard of care.
The FDA has released guidance on its compliance policy on reserve samples used in bioavailability and bioequivalence studies.
Sanofi is set to acquire Principia Biopharma Inc. for a total aggregate equity value of $3.68 billion, at $100 per share.
A preliminary analysis of data from the first COVID-19 pneumonia patients enrolled in the ODYSSEY trial revealed that tradipitant may expedite clinical improvement.
The European Medicines Agency (EMA) has accepted the marketing authorisation application for Evrysdi™ (risdiplam) as a treatment of spinal muscular atrophy (SMA).
Moderna will supply the US with at least 100 million doses of mRNA-1273, its COVID-19 vaccine candidate currently in Phase III clinical trials.
A study has found that three prescription drugs on the market cause unexpected side effects in the C. elegans worm, meaning they could have unknown effects in humans.
An agreement between AstraZeneca and the European Commission means the company will supply up to 400 million doses of its AZD1222 COVID-19 vaccine.
A report suggests that India’s CMO market has recently attracted investment from global private equity firms due to favourable government policies.
Preliminary data from a study has shown that convalescent plasma therapy is safe and can combat COVID-19 in severely ill patients.
A Phase III trial to investigate NT-300 (nitazoxanide extended-release tablets) as a treatment for mild or moderate COVID-19 has begun.
Bayer will acquire KaNDy Therapeutics Ltd for an upfront cost of $425 million to expand its drug development pipeline in women’s healthcare.
Randox is recalling COVID-19 testing kits in the UK as a precautionary measure as they do not meet the required safety standards, the MHRA has said.
The 'One Million Post-Authorisation Study' has been established to monitor the safety and effectiveness of COVID-19 vaccines in real-life conditions.
